Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.

It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.

The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma.

It also develops the"enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020.

Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.